Industry: Pharmaceuticals, Biotechnology
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. Through the company’s PORxinÔ technology platform, therapeutic candidates are generated by engineering the naturally occurring protein, proaerolysin. These proteins become potent anti-cancer agents when activated at a tumor site by specific proteases produced by cancer cells. Once activated, the drug punches holes in the cancer cells causing the contents to leak out and ultimately, cell death. Protox is in Phase I clinical trial with the lead compound, PRX302, for the treatment of localized prostate cancer. PRX302 is also being developed for treatment of benign prostatic hyperplasia. ( www.protoxtherapeutics.com )
Protox Therapeutics Inc.
1210-885 West Georgia Street
Vancouver, British Columbia V6C 3E8
Canada
Tel: (604) 688-0199
Fax: (604) 688-0173